Inebilizumab (MEDI-551) is a CD19-targeted humanized mAb that has potent ADCC activity in vitro and in vivo in preclinical studies.111 Inebilizumab monotherapy has been evaluated in phase 1 studies and showed acceptable toxicity and promising efficacy in patients with relapsed or refractory FL and DLBCL (NCT01957579).112 A phase 1/2 trial (NCT00983619) of inebilizumab alone and in combination with rituximab in FL, CLL, and DLBCL has recently been completed. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.